04.20.22
Bonafide, a company specializing in women’s health and wellness and over-the-counter medical products, recently acquired a patented, enhanced formulation of S-adenosylmethionine (SAM-e) branded as MSI-195. According to the company, this form of SAM-e has triple the bioavailability of standard competitor ingredients. With this acquisition, Bonafide now has more than 50 issued and pending patents that it owns or exclusively licenses.
SAM-e is a naturally-occurring compound found within the human body and regulates several processes. The high-bioavailability MSI-195 is formulated to support mood, joint health, and liver function, Bonafide said. As part of the acquisition, the company now owns all assets and worldwide patents related to the supplement.
“This unique and potent form of SAM-e has been studied as a potential pharmaceutical product over the past decade with a significant amount of safety, pre-clinical and clinical research supporting the enhanced bioavailability of this compound,” Jim Komorowski, Bonafide’s chief science officer, said. “We are very enthusiastic about MSI-195 because it has the potential to help women in a number of important areas, including mood. This technology will be added to Bonafide’s already robust pipeline that includes products for overactive bladder, sleep and other symptoms that are critical to women’s health.”
Bonafide specializes in natural products which target similar mechanistic pathways to pharmaceutical drugs, and each year, it invests millions of dollars into technological development and clinical trials. With the completion of the acquisition, the company plans to continue conducting clinical trials to leverage the ingredient into future Bonafide products.
“During my over 25 years in practice as an OB-GYN, I have seen that women want and need non-drug, natural alternatives for the treatment of symptoms from hormonal changes during menopause,” Alyssa Dweck, MD, Bonafide’s chief medical officer, said. “Bonafide is not only bringing unique and naturally powerful products to market, but also leveraging its national team of physician educators to bring this important information directly to mainstream doctors and other healthcare providers. In fact, Bonafide regularly interacts with more than 11,000 healthcare providers, including many of the top menopause specialists in the US.”
Since launching in 2018, Bonafide has expanded its suite of products to include five formulated for natural menopause relief solutions, along with a line of essential vitamins.
SAM-e is a naturally-occurring compound found within the human body and regulates several processes. The high-bioavailability MSI-195 is formulated to support mood, joint health, and liver function, Bonafide said. As part of the acquisition, the company now owns all assets and worldwide patents related to the supplement.
“This unique and potent form of SAM-e has been studied as a potential pharmaceutical product over the past decade with a significant amount of safety, pre-clinical and clinical research supporting the enhanced bioavailability of this compound,” Jim Komorowski, Bonafide’s chief science officer, said. “We are very enthusiastic about MSI-195 because it has the potential to help women in a number of important areas, including mood. This technology will be added to Bonafide’s already robust pipeline that includes products for overactive bladder, sleep and other symptoms that are critical to women’s health.”
Bonafide specializes in natural products which target similar mechanistic pathways to pharmaceutical drugs, and each year, it invests millions of dollars into technological development and clinical trials. With the completion of the acquisition, the company plans to continue conducting clinical trials to leverage the ingredient into future Bonafide products.
“During my over 25 years in practice as an OB-GYN, I have seen that women want and need non-drug, natural alternatives for the treatment of symptoms from hormonal changes during menopause,” Alyssa Dweck, MD, Bonafide’s chief medical officer, said. “Bonafide is not only bringing unique and naturally powerful products to market, but also leveraging its national team of physician educators to bring this important information directly to mainstream doctors and other healthcare providers. In fact, Bonafide regularly interacts with more than 11,000 healthcare providers, including many of the top menopause specialists in the US.”
Since launching in 2018, Bonafide has expanded its suite of products to include five formulated for natural menopause relief solutions, along with a line of essential vitamins.
